AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 111 min read$TREX

Fernandez Amy M. sold $53K of TREX

Fernandez Amy M. (SVP, CLO and Secretary) sold 1,050 shares of TREX CO INC (TREX) at $50.07 on 2026-08-07.

Original reporting
SEC EDGAR · Fernandez Amy M.
Published Aug 11, 2026, 8:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 8:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TREX
Neutral
low confidence
Mentioned
$TREX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TREXNeutralLow
01

Why it matters

The only new fact is the reported sale details (shares, price, total value, post-transaction holdings).

02

Market read

Traders may note insider selling activity, but there is no accompanying fundamental catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without additional filings or company catalysts, signal quality is low.

Relevance 3/10Novelty 3/10Timing: filed after-hours on 2026-08-11; transaction dated 2026-08-07

Background

The article is a SEC Form 4 insider transaction disclosure for TREX.

Company-level read

Ticker impact

$TREXNeutralLow confidence
Context

TREX disclosed an insider open-market sale by SVP, CLO and Secretary Fernandez Amy M. of 1,050 shares at $50.0689.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing reports a single insider sale size and price, without accompanying company news, earnings, guidance, or legal/regulatory developments.

Market effects

Sector

No clear sector read-through from a single insider sale disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Absence of a 10b5-1 plan could be interpreted as less predictable selling pressure, though the article provides no motive or follow-on buying.

Key entities

  • issuer
    TREX CO INC

    Company that filed the Form 4 insider transaction disclosure.

  • insider
    Fernandez Amy M.

    SVP, CLO and Secretary who sold 1,050 shares in an open-market sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TREX insider trading history →

Related articles

OCT 9
HighAI 8/10

TRex Bio, Clinical-Stage Immunology Biopharma, Files for Nasdaq Global Select Market IPO

TRex Bio filed for a Nasdaq IPO, offering 8,333,334 shares at $14.00 each, aiming to raise $116.7 million. The company, focused on immunoregulatory medicines, plans to use proceeds for clinical trials and general corporate purposes. Eli Lilly has shown interest in purchasing shares. TRex Bio's lead candidate, TRB-061, is in Phase 1b trials for atopic dermatitis, with data expected in mid-2027.

tradingview.com2 min
OCT 9
HighAI 8/10

TRex Bio raises $116.7 million in IPO priced at $14 a share

TRex Bio Inc. raised $116.7 million in its IPO, priced at $14 per share. J.P. Morgan and Evercore led the offering, indicating institutional confidence. The company focuses on immunology, an area of sustained investor interest. All shares were pre-allocated to institutional buyers, with the first public trading opportunity upcoming.

247wallst.com2 min
OCT 9
HighAI 8/10

TRex Bio IPO raises $116.7 million, prices at bottom of range

TRex Bio Inc. raised $116.7 million in its U.S. IPO, pricing shares at $14, the bottom of its $14-$16 range. The biotech company sold 8.3 million shares, giving it a market value of about $384 million. Proceeds will fund clinical trials for its lead drug candidate, TRB-061. Shares will trade on Nasdaq under the ticker TRXB. The company reported a net loss of $34.8 million in 2025, up from $3.1 million the prior year.

finance.yahoo.com2 min
OCT 9
HighAI 8/10

TRex Bio prices $117M IPO to support immune drug work

TRex Bio priced its IPO at $117M, selling 8.3M shares at $14 each, and will trade on Nasdaq under 'TRXB'. The company is developing immune drugs, with TRB-061 in Phase 1 trials and TRB-071 planned for testing. Eli Lilly, its largest shareholder, may also buy IPO shares. TRex has raised $220M in venture financing. Another biotech, Retension Pharmaceuticals, also went public with a $45M offering, highlighting increased biotech IPO activity in 2026.

finance.yahoo.com2 min
OCT 9
HighAI 9/10

TRex Bio, Inc. Prices $116.7M IPO at $14

TRex Bio priced 8.3M shares at $14 each, raising $116.7M in its IPO. Trading begins Oct. 9 on Nasdaq under ticker TRXB. Underwriters have a 30-day option for 1.25M more shares. The company plans to use proceeds for its clinical-stage immunology pipeline.

tradingview.com1 min